新生儿戒断综合征吗啡与美沙酮治疗后的神经发育结局
这项随机对照试验纳入116名足月新生儿戒断综合征患儿,比较吗啡与美沙酮治疗。结果显示两组在新生儿行为评估和18月龄Bayley量表及CBCL上无显著差异,但辅助使用苯巴比妥与较低Bayley评分和更多行为问题相关。
要点
- 吗啡与美沙酮治疗新生儿戒断综合征的短期和长期神经行为结局相似。
- 辅助使用苯巴比妥与18月龄Bayley评分较低及CBCL行为问题较多相关。
- 母亲心理困扰和婴儿健康问题与内化和总行为问题相关。
核心结论
- 吗啡或美沙酮治疗新生儿戒断综合征的婴儿短期和长期神经行为结局相似。
- 神经发育结局可能与需要苯巴比妥、婴儿整体健康和出生后照护环境有关。
研究设计与样本
- 随机对照试验,8个中心纳入116名足月新生儿戒断综合征婴儿,母亲维持使用美沙酮或丁丙诺啡。
- 99名婴儿(85%)出院时用NICU Network Neurobehavioral Scale评估,18月龄时83名(83.8%)用Bayley Scales of Infant and Toddler Development-Third Edition评估,77名(77.7%)用Child Behavior Checklist评估。
主要发现
- 主要分析显示治疗组间在NICU Network Neurobehavioral Scale、Bayley Scales和CBCL上无显著差异。
- 事后分析发现,辅助使用苯巴比妥的婴儿Bayley Scales评分较低且CBCL行为问题更多。
- 调整分析中,内化和总行为问题与苯巴比妥使用(P = .03;P = .04)、母亲心理困扰(均P < .01)和婴儿医学问题(均P = .02)相关。
- 外化问题与母亲心理困扰(P < .01)和母亲持续物质使用(P < .01)相关。
临床怎么用
- 对于新生儿戒断综合征,吗啡和美沙酮治疗在神经发育结局上未见显著差异。
- 应关注辅助使用苯巴比妥、婴儿健康问题及母亲心理困扰和持续物质使用对神经发育的潜在影响。
局限性
- 事后分析结果需谨慎解读。
- 部分婴儿失访,18月龄评估样本量减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effects of pharmacologic treatment of neonatal abstinence syndrome on neurodevelopmental outcome from a randomized, controlled trial. STUDY DESIGN: Eight sites enrolled 116 full-term newborn infants with neonatal abstinence syndrome born to mothers maintained on methadone or buprenorphine into a randomized trial of morphine vs methadone. Ninety-nine infants (85%) were evaluated at hospital discharge using the NICU Network Neurobehavioral Scale. At 18 months, 83 of 99 infants (83.8%) were evaluated with the Bayley Scales of Infant and Toddler Development-Third Edition and 77 of 99 (77.7%) with the Child Behavior Checklist (CBCL). RESULTS: Primary analyses showed no significant differences between treatment groups on the NICU Network Neurobehavioral Scale, Bayley Scales of Infant and Toddler Development-Third Edition, or CBCL. However in post hoc analyses, we found differences by atypical NICU Network Neurobehavioral Scale profile on the CBCL. Infants receiving adjunctive phenobarbital had lower Bayley Scales of Infant and Toddler Development-Third Edition scores and more behavior problems on the CBCL. In adjusted analyses, internalizing and total behavior problems were associated with use of phenobarbital (P = .03; P = .04), maternal psychological distress (measured by the Brief Symptom Inventory) (both P < .01), and infant medical problems (both P = .02). Externalizing problems were associated with maternal psychological distress (P < .01) and continued maternal substance use (P < .01). CONCLUSIONS: Infants treated with either morphine or methadone had similar short-term and longer term neurobehavioral outcomes. Neurodevelopmental outcome may be related to the need for phenobarbital, overall health of the infant, and postnatal caregiving environment. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01958476.
引用
- Czynski AJ, Davis JM, Dansereau LM, et al. Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome. J Pediatr. 2020. PMID: 31987653. doi:10.1016/j.jpeds.2019.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。